Sinopharm Group CoSHTDY -0.28%73 Return-on-Tangible-Asset is 1.88% as of Dec. 2025, which is 26% below its 10-year median of 2.54. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.32 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Sinopharm Group Co ranks worse than 60.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sinopharm Group Co's annualizedNet Income for the quarter that ended in Dec. 2025 was $1,048 Mil. Sinopharm Group Co's average total tangible assets for the quarter that ended in Dec. 2025 was $55,646 Mil. Therefore, Sinopharm Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 1.88%.
The historical rank and industry rank for Sinopharm Group Co's Return-on-Tangible-Asset or its related term are showing as below:
SHTDY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.85 Med: 2.54 Max: 3.41
Current: 1.85
During the past 13 years, Sinopharm Group Co's highest Return-on-Tangible-Asset was 3.41%. The lowest was 1.85%. And the median was 2.54%.
SHTDY's Return-on-Tangible-Asset is ranked worse than 60.17% of 118
companies
in the Medical Distribution industry
Industry Median: 2.305
vs SHTDY: 1.85
Sinopharm Group Co (OTCPK:SHTDY) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sinopharm Group Co Return-on-Tangible-Asset Related Terms
Sinopharm Group Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDY vs MCK, CAH, COR: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 1.88% mean?
Sinopharm Group Co (SHTDY) has a Return-on-Tangible-Asset of 1.88% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sinopharm Group Co and its competitors. This is 26% below median its historical median of 2.54. Over the past decade, Sinopharm Group Co's Return-on-Tangible-Asset has ranged from 1.85 to 3.41. According to the industry distribution chart, Sinopharm Group Co ranks #71 out of 118 companies in the Medical Distribution industry, placing it in the top 60.2%.
Is Sinopharm Group Co's Return-on-Tangible-Asset too high?
Sinopharm Group Co's current Return-on-Tangible-Asset of 1.88% is 26% below median its 10-year median of 2.54. Over the past 10 years, this metric has ranged from a low of 1.85 to a high of 3.41. The Medical Distribution industry median Return-on-Tangible-Asset is 2.31. Sinopharm Group Co's value of 1.88% is 18.4% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #71 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Return-on-Tangible-Asset compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #71 out of 118 companies for Return-on-Tangible-Asset. This places Sinopharm Group Co in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.31. Sinopharm Group Co's value of 1.88% is 18.4% below this benchmark. Historically, Sinopharm Group Co's own Return-on-Tangible-Asset has ranged from 1.85 to 3.41 over the past decade. While the company's 10-year median is 2.54 vs. the industry median of 2.31, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.31, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Return-on-Tangible-Asset of 1.88% is 18.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Return-on-Tangible-Asset is 1.88%, which is 26% below median its own 10-year median of 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.32, compared to a current price of $10.65 — trading 20% below its estimated fair value. The current Return-on-Tangible-Asset is 1.88%, which is 26% below median its 10-year median of 2.54 and 18.4% below the Medical Distribution industry median of 2.31. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Return-on-Tangible-Asset is 1.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.65 is trading 20% below its estimated GF Value™ of $13.32.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Return-on-Tangible-Asset: 1.88% (26% below median its 10-year median of 2.54)
GF Value™: $13.32 vs. price of $10.65 (20% below fair value)
Industry Position: 18.4% below the Medical Distribution median (#71 of 118)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
